Together, the aforementioned data show that although anti-TIM-3 mAbs alone are safe for tumor treatment, the combination treatment blocking the PD-1/PD-L1 axis demonstrates significantly greater effects, and the microsatellite status and ICB treatment history were closely related to efficacy. This evidence concerns the gene HAVCR2 and neoplasm.